Instrument Inactif

Communiqués CNS RESP OTC Bulletin Board

Actions

CNSOD

US12619C2008

Recherche biotechnologique et médicale

Communiqués

14/08	Emmaus Life Sciences Reports Quarterly Financial Results	BU
14/08	Emmaus Life Sciences : Reports Quarterly Financial ResultsAugust 14, 2026	PU
15/05	Emmaus Life Sciences : Reports Quarterly Financial ResultsMay 15, 2026	PU
15/05	Emmaus Life Sciences Reports Quarterly Financial Results	BU
31/03	Emmaus Life Sciences Reports Annual Financial Results	BU
30/12	Emmaus Life Sciences Announces Strategic Transaction	BU
26/06/25	Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements	PR
15/04/25	Emmaus Life Sciences Reports 2024 Financial Results	PR
19/11/24	Emmaus Life Sciences : Reports Improved Quarterly Financial Results Form 8 K	PU
19/11/24	Emmaus Life Sciences Reports Improved Quarterly Financial Results	PR
06/11/24	Emmaus Life Sciences : Management Change/Compensation Form 8 K	PU
10/09/24	Emmaus Life Sciences Reports Quarterly Financial Results	PR
23/07/24	Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer	PR
03/07/24	Emmaus Life Sciences Reports 2023 Financial Results	PR
28/05/24	Emmaus Life Sciences : Certificate of Incorporation/Bylaws - Form 8-K	PU
15/04/24	Emmaus Life Sciences Reports Delayed Filing of Annual Report	PR
02/02/24	Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico	PR
20/12/23	Emmaus Life Sciences : Material Agreement - Form 8-K	PU
14/11/23	Emmaus Life Sciences Reports Q3 2023 Financial Results	PR
23/08/23	Emmaus Life Sciences Reports Management Changes	PR
14/08/23	Emmaus Life Sciences Reports Q2 2023 Financial Results	PR
14/08/23	Emmaus Life Sciences : Reports Q2 2023 Financial Results - Form 8-K	PU
13/07/23	Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman	PR
31/05/23	Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA	PR
15/05/23	Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update	PR